Medicus Pharma Ltd ( (MDCX) ) has issued an announcement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medicus Pharma Ltd. announced the commencement of patient recruitment for its SKNJCT-004 phase 2 clinical study at Cleveland Clinic Abu Dhabi, aimed at non-invasively treating basal cell carcinoma of the skin. This development is part of the company’s broader strategy to introduce novel treatments in the market, with the study being coordinated by Insights Research Organization and Solutions in the UAE. The company is also progressing with its SKNJCT-003 study in the United States, which has shown promising interim results. Additionally, Medicus has expanded its portfolio by acquiring Antev Limited, a UK-based biotech company, further strengthening its position in the biotech industry.
The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets. The company is involved in multiple countries and is listed on NASDAQ under the ticker MDCX.
Average Trading Volume: 413,623
Technical Sentiment Signal: Sell
Current Market Cap: $33.49M
For an in-depth examination of MDCX stock, go to TipRanks’ Overview page.